<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869346</url>
  </required_header>
  <id_info>
    <org_study_id>NAOOP</org_study_id>
    <nct_id>NCT03869346</nct_id>
  </id_info>
  <brief_title>Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients</brief_title>
  <official_title>Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yichang Humanwell Pharmaceutical Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: This study aimed to investigate the impact of CYP3A4*1G genetic polymorphism on
      non-analgesic effects of fentanyl in Chinese Han patients. Methods: 200 patients receiving
      elective surgery under general anesthesia were recruited into this study. Venous blood was
      withdrawn for genotyping of CYP3A4*1G before operation. Fentanyl 2 µg/kg was administered
      preoperatively. Bispectral Index (BIS), Respiratory rate(RR), etc at Tb (entering room), T0
      (drug administration), T1 (2min), T2 (4min), T3(6min), T4(8min), T5(10min), T6(20min) were
      recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bispectral index</measure>
    <time_frame>20 min after administration</time_frame>
    <description>bispectral index(BIS): assessing the sedation, placed on the patient's forehead, BIS values 0-100, and the higher score means patients are more conscious</description>
  </primary_outcome>
  <primary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>20 min after administration</time_frame>
    <description>Number of breaths per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP3A4*1G Polymorphism</measure>
    <time_frame>1 week after operation</time_frame>
    <description>The patients were classified by genotype including wild‑type homozygote (CYP3A4*1/*1, GG), mutant heterozygote (CYP3A4*1/*1G, GA), and mutant homozygote (CYP3A4*1G/*1G, AA).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fentanyl</condition>
  <arm_group>
    <arm_group_label>GG</arm_group_label>
    <description>wild‑type homozygote (CYP3A4*1/*1, GG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA</arm_group_label>
    <description>mutant heterozygote (CYP3A4*1/*1G, GA),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <description>mutant homozygote (CYP3A4*1G/*1G, AA)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      200 blood samples were withdrawn
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        200 Chinese Han patients receiving elective surgery under general anesthesia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists GradeⅠ－II,Patients undergo elective surgery for
             benign Reproductive diseases (including laparoscopic ovarian cyst removal,
             laparoscopic tubal ligation, laparoscopic tubal drainage, laparoscopic salpingoplasty,
             etc.) or breast disease.

          -  Aged 18-45 years

          -  Body Mass Index 18-25kg/m2,body weight 40-65 kilograms

          -  Agreed to participate the research

        Exclusion Criteria:

          -  Difficult airway

          -  upper respiratory tract infection within 2 weeks

          -  history of allergy or long-term use of propofol and opioids

          -  self-rating anxiety scale before operation indicates anxiety

          -  pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Feng, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Yan, MD</last_name>
    <phone>13811319638</phone>
    <email>yanqi04@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Feng, MD</last_name>
    <phone>01088325581</phone>
    <email>yifeng65@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qi yan</last_name>
      <phone>8613811319638</phone>
      <email>yanqi04@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Yanqi</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

